Combining immunotherapy with PARP inhibitors. Is it possible to find the way through?
作者信息
Papageorgiou Georgios I, Skouteris Nikolaos, Eleftheriou Kleopatra, Kosmas Christos
机构信息
2nd Medical Oncology Department, IASO General Clinic, Athens, Greece.
Division of Medical Oncology & Hematopoietic Cell Transplant Unit, Department of Medicine, "Metaxa" Cancer Hospital, Piraeus, Greece.
出版信息
Immunotherapy. 2024;16(16-17):999-1003. doi: 10.1080/1750743X.2024.2398412. Epub 2024 Sep 13.
Abstract
摘要
相似文献
1
Combining immunotherapy with PARP inhibitors. Is it possible to find the way through?将免疫疗法与PARP抑制剂相结合。能否找到出路？
Immunotherapy. 2024;16(16-17):999-1003. doi: 10.1080/1750743X.2024.2398412. Epub 2024 Sep 13.
2
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.用于治疗卵巢癌的聚（ADP - 核糖）聚合酶（PARP）抑制剂。
Cochrane Database Syst Rev. 2015 May 20;2015(5):CD007929. doi: 10.1002/14651858.CD007929.pub3.
3
PARP Inhibitors for Breast Cancer Treatment: A Review.PARP 抑制剂在乳腺癌治疗中的应用：综述。
JAMA Oncol. 2024 May 1;10(5):658-670. doi: 10.1001/jamaoncol.2023.7322.
4
SIK2 inhibitor SIC-19 enhances the sensitivity of PARP inhibitors in triple-negative breast cancers and pancreatic cancers.SIK2抑制剂SIC-19增强了三阴性乳腺癌和胰腺癌对PARP抑制剂的敏感性。
Oncol Res. 2025 Jun 26;33(7):1757-1767. doi: 10.32604/or.2025.062539. eCollection 2025.
5
Oncolytic reovirus enhances the effect of CEA immunotherapy when combined with PD1-PDL1 inhibitor in a colorectal cancer model.在结直肠癌模型中，溶瘤呼肠孤病毒与PD1-PDL1抑制剂联合使用时可增强CEA免疫疗法的效果。
Immunotherapy. 2025 Apr;17(6):425-435. doi: 10.1080/1750743X.2025.2501926. Epub 2025 May 12.
7
Therapeutic approach for triple-negative breast Cancer through poly (ADP-ribose) Polymerase-1 inhibitors: Current update.通过聚（ADP-核糖）聚合酶-1抑制剂治疗三阴性乳腺癌的方法：最新进展
Bioorg Chem. 2025 May 19;163:108558. doi: 10.1016/j.bioorg.2025.108558.
8
Use of PARP inhibitors in prostate cancer: from specific to broader application.PARP 抑制剂在前列腺癌中的应用：从特定到更广泛的应用。
Front Endocrinol (Lausanne). 2023 Apr 21;14:1164067. doi: 10.3389/fendo.2023.1164067. eCollection 2023.
9
Machine learning-based screening and molecular simulations for discovering novel PARP-1 inhibitors targeting DNA repair mechanisms for breast cancer therapy.基于机器学习的筛选和分子模拟，用于发现针对乳腺癌治疗中DNA修复机制的新型PARP-1抑制剂。
Mol Divers. 2025 Feb 3. doi: 10.1007/s11030-025-11119-4.
10
Radiation-Based Multi-Modal Therapy Combining with Immunotherapy to Develop a Vaccine-Like Effective Treatment for Triple-Negative Breast Cancer.基于放射的多模态疗法联合免疫疗法以开发一种类似疫苗的三阴性乳腺癌有效治疗方法。
Breast Cancer (Dove Med Press). 2025 Jun 10;17:483-496. doi: 10.2147/BCTT.S518625. eCollection 2025.
本文引用的文献
1
PARP Inhibitors: Strategic Use and Optimal Management in Ovarian Cancer.PARP抑制剂：卵巢癌的策略性应用与优化管理
Cancers (Basel). 2024 Feb 25;16(5):932. doi: 10.3390/cancers16050932.
2
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.一线 talazoparib 联合恩扎卢胺治疗 HRR 缺陷转移性去势抵抗性前列腺癌：III 期 TALAPRO-2 试验。
Nat Med. 2024 Jan;30(1):257-264. doi: 10.1038/s41591-023-02704-x. Epub 2023 Dec 4.
3
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.奥拉帕利联合度伐利尤单抗，联合或不联合贝伐珠单抗，用于 PARP 抑制剂初治铂类敏感复发性卵巢癌的治疗：一项 II 期多队列研究。
Clin Cancer Res. 2024 Jan 5;30(1):50-62. doi: 10.1158/1078-0432.CCR-23-2249.
4
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.度伐利尤单抗联合卡铂/紫杉醇序贯度伐利尤单抗维持治疗（联合或不联合奥拉帕利）作为晚期子宫内膜癌一线治疗：III期DUO-E试验
J Clin Oncol. 2024 Jan 20;42(3):283-299. doi: 10.1200/JCO.23.02132. Epub 2023 Oct 21.
5
Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors.当前对卵巢癌为何对免疫检查点抑制剂产生耐药性的认识。
Int J Mol Sci. 2023 Jun 29;24(13):10859. doi: 10.3390/ijms241310859.
6
Crosstalk between immune checkpoint and DNA damage response inhibitors for radiosensitization of tumors.免疫检查点与 DNA 损伤反应抑制剂的串扰增强肿瘤放疗增敏作用。
Strahlenther Onkol. 2023 Dec;199(12):1152-1163. doi: 10.1007/s00066-023-02103-8. Epub 2023 Jul 7.
7
Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between.早期三阴性乳腺癌之旅：起点、终点及其间的一切。
Am Soc Clin Oncol Educ Book. 2023 Jun;43:e390464. doi: 10.1200/EDBK_390464.
8
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.奥拉帕利联合贝伐珠单抗一线维持治疗卵巢癌：PAOLA-1/ENGOT-ov25 试验的最终总生存结果。
Ann Oncol. 2023 Aug;34(8):681-692. doi: 10.1016/j.annonc.2023.05.005. Epub 2023 May 19.
9
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies.辅助奥拉帕利治疗 HER2 阴性早期乳腺癌的胚系 BRCA 携带者：证据与争议。
Oncologist. 2023 Jul 5;28(7):565-574. doi: 10.1093/oncolo/oyad123.
10
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.帕博利珠单抗联合化疗治疗晚期子宫内膜癌。
N Engl J Med. 2023 Jun 8;388(23):2159-2170. doi: 10.1056/NEJMoa2302312. Epub 2023 Mar 27.
Zotero 插件